STOK
Stoke TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
STOK Profile
Stoke Therapeutics, Inc.
A biotech company that develops antisense oligonucleotide medicines to target RNA splicing to enhance gene expression
Biological Technology
--
06/19/2019
NASDAQ Stock Exchange
128
12-31
Common stock
45 Wiggins Avenue, Bedford, MA 01730
--
Stoke Therapeutics, Inc., founded in June 2014, was incorporated under the laws of the State of Delaware. The company is an early-stage biopharmaceutical company that has pioneered new ways to treat the underlying causes of serious genetic diseases by precisely up-regulating protein expression. The company is developing novel antisense oligonucleotide (ASO) drugs that target ribonucleic acid or RNA and modulate precursor-messenger RNA or pre-mRNA, up-regulating protein expression to near normal levels with appropriate specificity when needed. The company uses a proprietary technology platform to target enhanced nuclear gene output, or TANGO, to design ASO to up-regulate the expression of proteins in individual patients' genes. The Company's methods are designed to deliver disease-modifying therapies to a wide range of relevant tissues, including the central nervous system, or central nervous system, eyes, kidneys and liver, in a highly precise, durable and controllable manner.
